592 related articles for article (PubMed ID: 11090355)
1. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3.
McDonald PH; Chow CW; Miller WE; Laporte SA; Field ME; Lin FT; Davis RJ; Lefkowitz RJ
Science; 2000 Nov; 290(5496):1574-7. PubMed ID: 11090355
[TBL] [Abstract][Full Text] [Related]
2. Signal transduction. An arresting start for MAPK.
Pouysségur J
Science; 2000 Nov; 290(5496):1515-8. PubMed ID: 11185509
[TBL] [Abstract][Full Text] [Related]
3. The beta-arrestin-2 scaffold protein promotes c-Jun N-terminal kinase-3 activation by binding to its nonconserved N terminus.
Guo C; Whitmarsh AJ
J Biol Chem; 2008 Jun; 283(23):15903-11. PubMed ID: 18408005
[TBL] [Abstract][Full Text] [Related]
4. Dynamic interaction between the dual specificity phosphatase MKP7 and the JNK3 scaffold protein beta-arrestin 2.
Willoughby EA; Collins MK
J Biol Chem; 2005 Jul; 280(27):25651-8. PubMed ID: 15888437
[TBL] [Abstract][Full Text] [Related]
5. Identification of a motif in the carboxyl terminus of beta -arrestin2 responsible for activation of JNK3.
Miller WE; McDonald PH; Cai SF; Field ME; Davis RJ; Lefkowitz RJ
J Biol Chem; 2001 Jul; 276(30):27770-7. PubMed ID: 11356842
[TBL] [Abstract][Full Text] [Related]
6. JSAP1, a novel jun N-terminal protein kinase (JNK)-binding protein that functions as a Scaffold factor in the JNK signaling pathway.
Ito M; Yoshioka K; Akechi M; Yamashita S; Takamatsu N; Sugiyama K; Hibi M; Nakabeppu Y; Shiba T; Yamamoto KI
Mol Cell Biol; 1999 Nov; 19(11):7539-48. PubMed ID: 10523642
[TBL] [Abstract][Full Text] [Related]
7. beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation.
Tohgo A; Pierce KL; Choy EW; Lefkowitz RJ; Luttrell LM
J Biol Chem; 2002 Mar; 277(11):9429-36. PubMed ID: 11777902
[TBL] [Abstract][Full Text] [Related]
8. Silent scaffolds: inhibition OF c-Jun N-terminal kinase 3 activity in cell by dominant-negative arrestin-3 mutant.
Breitman M; Kook S; Gimenez LE; Lizama BN; Palazzo MC; Gurevich EV; Gurevich VV
J Biol Chem; 2012 Jun; 287(23):19653-64. PubMed ID: 22523077
[TBL] [Abstract][Full Text] [Related]
9. The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation.
Tohgo A; Choy EW; Gesty-Palmer D; Pierce KL; Laporte S; Oakley RH; Caron MG; Lefkowitz RJ; Luttrell LM
J Biol Chem; 2003 Feb; 278(8):6258-67. PubMed ID: 12473660
[TBL] [Abstract][Full Text] [Related]
10. Stable interaction between beta-arrestin 2 and angiotensin type 1A receptor is required for beta-arrestin 2-mediated activation of extracellular signal-regulated kinases 1 and 2.
Wei H; Ahn S; Barnes WG; Lefkowitz RJ
J Biol Chem; 2004 Nov; 279(46):48255-61. PubMed ID: 15355986
[TBL] [Abstract][Full Text] [Related]
11. Scaffolding mechanism of arrestin-2 in the cRaf/MEK1/ERK signaling cascade.
Qu C; Park JY; Yun MW; He QT; Yang F; Kim K; Ham D; Li RR; Iverson TM; Gurevich VV; Sun JP; Chung KY
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507982
[TBL] [Abstract][Full Text] [Related]
12. Arrestin-3 binds c-Jun N-terminal kinase 1 (JNK1) and JNK2 and facilitates the activation of these ubiquitous JNK isoforms in cells via scaffolding.
Kook S; Zhan X; Kaoud TS; Dalby KN; Gurevich VV; Gurevich EV
J Biol Chem; 2013 Dec; 288(52):37332-42. PubMed ID: 24257757
[TBL] [Abstract][Full Text] [Related]
13. Identification of arrestin-3-specific residues necessary for JNK3 kinase activation.
Seo J; Tsakem EL; Breitman M; Gurevich VV
J Biol Chem; 2011 Aug; 286(32):27894-901. PubMed ID: 21715332
[TBL] [Abstract][Full Text] [Related]
14. How does arrestin assemble MAPKs into a signaling complex?
Song X; Coffa S; Fu H; Gurevich VV
J Biol Chem; 2009 Jan; 284(1):685-695. PubMed ID: 19001375
[TBL] [Abstract][Full Text] [Related]
15. Platelet-activating factor-induced clathrin-mediated endocytosis requires beta-arrestin-1 recruitment and activation of the p38 MAPK signalosome at the plasma membrane for actin bundle formation.
McLaughlin NJ; Banerjee A; Kelher MR; Gamboni-Robertson F; Hamiel C; Sheppard FR; Moore EE; Silliman CC
J Immunol; 2006 Jun; 176(11):7039-50. PubMed ID: 16709866
[TBL] [Abstract][Full Text] [Related]
16. Receptor sequestration in response to β-arrestin-2 phosphorylation by ERK1/2 governs steady-state levels of GPCR cell-surface expression.
Paradis JS; Ly S; Blondel-Tepaz É; Galan JA; Beautrait A; Scott MG; Enslen H; Marullo S; Roux PP; Bouvier M
Proc Natl Acad Sci U S A; 2015 Sep; 112(37):E5160-8. PubMed ID: 26324936
[TBL] [Abstract][Full Text] [Related]
17. Association of beta-Arrestin 1 with the type 1A angiotensin II receptor involves phosphorylation of the receptor carboxyl terminus and correlates with receptor internalization.
Qian H; Pipolo L; Thomas WG
Mol Endocrinol; 2001 Oct; 15(10):1706-19. PubMed ID: 11579203
[TBL] [Abstract][Full Text] [Related]
18. A beta-arrestin-dependent scaffold is associated with prolonged MAPK activation in pseudopodia during protease-activated receptor-2-induced chemotaxis.
Ge L; Ly Y; Hollenberg M; DeFea K
J Biol Chem; 2003 Sep; 278(36):34418-26. PubMed ID: 12821670
[TBL] [Abstract][Full Text] [Related]
19. Arrestin-dependent activation of JNK family kinases.
Zhan X; Kook S; Gurevich EV; Gurevich VV
Handb Exp Pharmacol; 2014; 219():259-80. PubMed ID: 24292834
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II type 1 receptor variants alter endosomal receptor-β-arrestin complex stability and MAPK activation.
Cao Y; Kumar S; Namkung Y; Gagnon L; Cho A; Laporte SA
J Biol Chem; 2020 Sep; 295(38):13169-13180. PubMed ID: 32703898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
